Use of composite endpoints in clinical trials.
The success of a confirmatory clinical trial designed to demonstrate the efficacy of a new treatment is highly dependent on the choice of valid primary efficacy endpoint(s). The optimal clinical and statistical situation for the design of such a trial is one that starts with the selection of a single primary efficacy endpoint that completely characterizes the disease under study, admits the most efficient clinical and statistical evaluation of treatment effect, and provides clear and broad interpretation of drug effect. For diseases with multidimensional presentations, however, the selection of such an endpoint may not be possible, and so drug effectiveness is often characterized by the use of composite or multiple efficacy endpoint(s). The use of a composite endpoint with components that are only slightly correlated but not quite dissimilar in their recognized clinical relevance could lead to a more sensitive statistical test and thus, adequately powered trials with smaller sample size. This note discusses the utility of composite endpoints in clinical trials and some of the common approaches for dealing with multiplicity arising from their use.
Biometrics, Vertex Pharmaceuticals, Boston, MA, U.S.A.
Abdul J
AJ
Sankoh
Haihong
H
Li
Ralph B
RB
D'Agostino
D001699:Biometry / Q000379:methods; D002986:Clinical Trials as Topic / Q000379:methods*; D004341:Drug Evaluation / Q000379:methods*; D023381:Endpoint Determination / Q000379:methods*; D006801:Humans; D009026:Mortality; D016896:Treatment Outcome
clinical relevance; clinical utility; flexible statistical approaches; single primary endpoint; types of endpoints